fadeucravacitinib | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

70 results for “fadeucravacitinib”

Trials

View all 63 →

Deucravacitinib Rosacea

33 participants · First posted Aug 1, 2024

Active, not recruiting

Deucravacitinib Adherence Study

40 participants · First posted Oct 7, 2022

Deucravacitinib in PG

10 participants · First posted Apr 20, 2023

Drugs

Deucravacitinib(Sotyktu)

Manufacturer: Bristol Myers Squibb

Conditions: Severe Plaque psoriasis, Moderate Plaque psoriasis +1 more

C₂₀H₂₂N₈O₃ · Rx

News

Innocare's Oral Psoriasis Drug Fadeucravacitinib Meets Primary Goal in Phase III Trial, Regulatory Filing Planned

Deucravacitinib Demonstrates Superior Efficacy in Cutaneous Lupus Erythematosus Treatment

Deucravacitinib Shows Efficacy in Psoriasis Patients Who Failed Apremilast Treatment

Page 1 of 7